Damora Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
DMRA$24.07+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets · (unaudited) | ||
| Current assets | ||
| Cash and cash equivalents | $349,656 | $257,624 |
| Marketable securities | 178,822 | — |
| Prepaid expenses and other current assets | 2,839 | 2,799 |
| Total current assets | 531,317 | 260,423 |
| Operating lease right-of-use asset | 830 | 68 |
| Other assets, noncurrent | 480 | 36 |
| Total assets | $532,627 | $260,527 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $6,084 | $444 |
| Accrued expenses and other current liabilities | 12,830 | 2,401 |
| Paramora warrant obligation | 11,862 | — |
| Related party accounts payable and other current liabilities | 4,963 | 17,221 |
| Operating lease liabilities, current | 153 | — |
| Total current liabilities | 35,892 | 20,066 |
| Operating lease liabilities, noncurrent | 946 | 53 |
| Other liabilities, noncurrent | 28 | 28 |
| Total liabilities | 36,866 | 20,147 |
| Commitments and contingencies (Note 9) | ||
| Mezzanine equity | ||
| Preferred shares, par value of $0.00001 per share; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares and 159 shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | 1,341 |
| Shareholders’ equity | ||
| Series B non-voting convertible preferred shares, par value of $0.00001 per share; 16,366 shares authorized, issued and outstanding at September 30, 2026 and December 31, 2025 | 117,621 | 117,621 |
| Series C non-voting convertible preferred shares, par value of $0.00001 per share; 43,882 shares authorized at September 30, 2026 and December 31, 2025; 1,722 and 43,882 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 12,376 | 297,291 |
| Ordinary shares, par value of $0.00001 per share; 500,000,000 shares authorized at September 30, 2026 and 300,000,000 shares authorized at December 31, 2025; 61,904,742 and 1,597,321 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 1 | — |
| Additional paid-in capital | 944,307 | 310,688 |
| Accumulated deficit | (578,311) | (487,363) |
| Accumulated other comprehensive (loss) income | (233) | 802 |
| Total shareholders’ equity | 495,761 | 239,039 |
| Total liabilities and shareholders’ equity | $532,627 | $260,527 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.